Source comparison
PT-141 MC4R Mechanism: Research vs Clinical vs Commercial Comparison
Purity Standard ≥98% HPLC-verified, batch COA required USP monograph compliance, FDA-approved manufacturing Variable (claimed 95–99%, COA often not third-party verified) Dosage Form Lyophilized powder requiring reconstitution with bacteriostatic water Pre-fill
This comparison does not assign a generated winner or score.
- Purity Standard
- ≥98% HPLC-verified, batch COA required
- USP monograph compliance, FDA-approved manufacturing
- Variable (claimed 95–99%, COA often not third-party verified)
- Dosage Form
- Lyophilized powder requiring reconstitution with bacteriostatic water
- Pre-filled autoinjector, 1.75mg/0.3mL sterile solution
- Lyophilized vials (dosing precision depends on user reconstitution accuracy)
- Regulatory Oversight
- Sold for research use only under exemptions for non-clinical studies
- FDA-approved drug product under NDA 211367, prescription required
- Unregulated (often marketed as 'research chemicals' to bypass drug approval requirements)
- Cost Per Dose
- $45–$80 per 10mg vial (researcher purchases in bulk)
- ~$950 per dose (single-use autoinjector, insurance rarely covers)
- $30–$60 per 10mg vial (consumer direct purchase)
- Mechanism Certainty
- Confirmed MC4R selectivity through receptor binding assays
- Same active molecule as research grade, clinical efficacy proven in Phase 3 trials
- Mechanism assumed identical if peptide sequence is correct (no post-market verification)
- Professional Assessment
- Real Peptides supplies research-grade PT-141 with third-party purity verification for laboratory use only. Not for human administration. Clinical outcomes require pharmaceutical-grade formulations under prescriber supervision.